Executive vice president and chief strategy officer, Hengrui Pharma
Appears in 1 story
Led the HRS-1596 licensing agreement
Novo Nordisk will pay China's Hengrui Pharma $300 million upfront to license an experimental weight-loss pill designed for once-weekly use. The deal, which could reach $2.6 billion with milestone payments, gives Novo exclusive rights to HRS-1596 outside Greater China.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
